157 related articles for article (PubMed ID: 26041618)
1. Would you bet on PET? Evaluation of the significance of positive PET scan results post-microwave ablation for non-small cell lung cancer.
Zaheer SN; Whitley JM; Thomas PA; Steinke K
J Med Imaging Radiat Oncol; 2015 Dec; 59(6):702-12. PubMed ID: 26041618
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous microwave ablation for early-stage non-small cell lung cancer (NSCLC) in the elderly: a promising outlook.
Acksteiner C; Steinke K
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):82-90. PubMed ID: 25335916
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
5. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
7. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
8. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
Alafate A; Shinya T; Okumura Y; Sato S; Hiraki T; Ishii H; Gobara H; Kato K; Fujiwara T; Miyoshi S; Kaji M; Kanazawa S
Acta Med Okayama; 2013; 67(2):105-12. PubMed ID: 23603927
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
[TBL] [Abstract][Full Text] [Related]
10. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
11. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
12. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation.
Deandreis D; Leboulleux S; Dromain C; Auperin A; Coulot J; Lumbroso J; Deschamps F; Rao P; Schlumberger M; de Baère T
Radiology; 2011 Jan; 258(1):270-6. PubMed ID: 21045185
[TBL] [Abstract][Full Text] [Related]
13. Is mediastinoscopy still the gold standard to evaluate mediastinal lymph nodes in patients with non-small cell lung carcinoma?
Sivrikoz CM; Ak I; Simsek FS; Döner E; Dündar E
Thorac Cardiovasc Surg; 2012 Mar; 60(2):116-21. PubMed ID: 21692019
[TBL] [Abstract][Full Text] [Related]
14. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer.
Pou Ucha JL; Nogueiras Alonso JM; Alvarez Paez AM; Suarez Arfenoni BA; Puig AS; Lopez Lopez AM; Barandela Salgado J; Campos Villarino LM; Casal Rivas M; Guitian Iglesias R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):301-7. PubMed ID: 23084012
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
17. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Tauhardt E; Reissig A; Winkens T; Freesmeyer M
Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
[TBL] [Abstract][Full Text] [Related]
18. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
[TBL] [Abstract][Full Text] [Related]
19. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]